|
Réf :
 Andre
F, Grunenwald D, Pujol JL, Girard P, Dujon A, Brouchet L, Brichon PY,
Westeel V, Le Chevalier T. Patterns of relapse of N2 nonsmall-cell
lung carcinoma patients treated with preoperative chemotherapy: should
prophylactic cranial irradiation be reconsidered? Cancer
2001;91:2394-400
Berghmans
T, Paesmans M, Meert AP, Mascaux C, Lothaire P, Lafitte JJ, Sculier JP. Survival
improvement in resectable non-small cell lung cancer with (neo)adjuvant
chemotherapy: results of a meta-analysis of the literature. Lung
Cancer 2005;49:13-23
Clamon GH, Parekh KR. Mortality related to neoadjuvant therapy and surgery for stage III non-small-cell lung cancer. Clin Lung Cancer 2008;9:213-6
Depierre A, Milleron B, Moro-Sibilot D, Chevret S et al. Preoperative
chemotherapy followed by surgery compared with primary surgery in
resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J
Clin Oncol 2002;20:247-53
Dooms
C, Verbeken E, Stroobants S, Nackaerts K, De Leyn P, Vansteenkiste J. Prognosis
stratification of stage IIIA-N2 non-small-cell lung cancer after induction
chemotherapy: A model based on the combination of morphometric-pathologic
response in mediastinal nodes and primary tumor response on serial 18-fluoro-deoxy-glucose
positron emission tomography. J Clin Oncol 2008;26:1128-34
Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, Hatton
M, Hopwood P, Manegold C, Schramel F, Smit H, van Meerbeeck J, Nankivell
M, Parmar M, Pugh C, Stephens R. Preoperative chemotherapy in patients
with resectable non-small cell lung cancer: results of the MRC LU22/NVALT
2/EORTC 08012 multicentre randomised trial and update of systematic review.
Lancet 2007;369:1929-37
Martini N, Kris MG, Flehinger BJ, Gralla RJ, Bains MS, Burt ME, Heelan R,
McCormack PM, Pisters KMW, Rigas JR, Rusch VW, Ginsberg RJ. Preoperative
chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering
experience with 136 patients. Ann Thorac Surg 1993;55:1365-74
Nagai K, Tsuchiya R, Mori T, Tada H, Ichinose Y, Koike T, Kato H; Lung Cancer
Surgical Study Group of the Japan Clinical Oncology Group. A randomized
trial comparing induction chemotherapy followed by surgery with surgery
alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG
9209). J Thorac Cardiovasc Surg 2003;125:254-60
Pass HI,
Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized
trial of neoadjuvant therapy for lung cancer: interim analysis. Ann
Thorac Surg 1992;53:992-8
Pisters KMW, Ginsberg RJ, Giroux DJ, Putnam JB, Kris MG, Johnson DH, Roberts JR,
Mault J, Crowley JJ, Bunn PA on behalf of the Bimodality Lung Oncology
Team (BLOT). Induction chemotherapy before surgery for early-stage
lung cancer: a novel approach. J Thorac Cardiovasc Surg 2000;119:429-39
Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S,
Roig J, Olazabal A, Canela M, Ariza A, Skacel Z, Morera-Prat J, Abad
A. A randomized trial comparing preoperative chemotherapy plus
surgery with surgery alone in patients with non-small-cell lung
cancer. N Engl J Med 1994;330:153-8
Roth JA, Fossella F, Komaki R, Ryan B, Putnam JB, Lee JS, Dhingra H, De Caro L,
Chasen M, McGavran M, Neely Atkinson E, Hong WK. A randomized trial
comparing perioperative chemotherapy and surgery with surgery alone in
resecable stage IIIA non-small-cell lung cancer. J Natl Cancer
Inst 1994;86:673-80
Shepherd FA. Induction
chemotherapy for locally advanced non-small cell lung cancer. Ann Thorac Surg 1993;55:1365-74
Siegenthaler MP, Pisters KM, Merriman KW, Roth JA, Swisher SG, Walsh GL, Vaporciyan AA,
Smythe WR, Putnam JB. Preoperative chemotherapy for lung cancer does
not increase surgical morbidity. Ann Thorac Surg 2001;71:1105-12
Van
Meerbeeck JP, Kramer GWPM, Van Schil PEY, Legrand C, Smit EF, Schramel
F, Tjan-Heijnen VC, Biesma B, Debruyne C, Van Zandwijk N, Splinter TAW,
Giaccone G. Randomized controlled trial of resection versus radiotherapy
after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
J Natl Cancer Inst 2007;99:442-50
|
La 
Pouvoir
réaliser une résection complète
chez un malade atteint de cancer bronchique primitif localisé mais a priori
trop étendu
pour une chirurgie d'exérèse curatrice de première intention (
